Fig. 2: In vivo functional comparison of lymphoma and healthy donor CAR T cells. | Leukemia

Fig. 2: In vivo functional comparison of lymphoma and healthy donor CAR T cells.

From: Gene-edited healthy donor CAR T cells show superior anti-tumour activity compared to CAR T cells derived from patients with lymphoma in an in vivo model of high-grade lymphoma

Fig. 2

a Schematic diagram of in vivo experiment design with Raji xenograft model. Mice are injected i.v. with 1 × 105 Raji luciferase cells on day −5, on day 0 they are injected i.v. with 5 × 105 CAR+ T cells. Tumour growth is monitored twice weekly with BLI following IP injection of luciferin. b Raji cell growth is faster in lymphoma CAR T-treated mice compared to HD and HD TCR− CAR T-treated mice. Mean flux and standard error margin is shown for each treatment group with data pooled from two experiments. Day 9 flux HD CAR vs. lymphoma CAR p = 0.036, HD TCR− CAR vs. lymphoma CAR p = 0.0365, one-way ANOVA p ≤ 0.0001 with the Tukey’s multiple comparisons test for paired analysis. c Survival curves demonstrate improved survival in HD compared to lymphoma CAR T-treated mice (p = 0.0076, log rank test), but comparable survival between HD and HD TCR− CAR T-treated mice. d Median overall survival of mice correlated with the proportion of pre-infusion CAR T cells, which were CD8+CD27+PD-1− (Spearman r = 0.7762, p = 0.0016) (n = 6 HD, n = 3 HD TCR− and n = 5 lymphoma CAR T products, each tested in 3–5 mice e.g. n = 27 HD, n = 13 HD TCR− and n = 20 lymphoma treated mice). e Mice were weighed twice a week during the experiment and results are plotted against time.

Back to article page